Lanosterol

Lanosterol

SCHEMBL244737

CC(C)=CCC[C@H](C)[C@@H]1CC[C@]2(C)C3=C(CC[C@@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
USP2 O75604 2/20 1.00
ALDH1A1 P00352 2/20 1.00
CYP3A4 P08684 2/20 1.00
ALOX15 P16050 2/20 1.00
CRYAB P02511 2/20 1.00
LMNA P02545 1/20 1.00
PTGES O14684 4/20 0.79
FNTA P49354 1/20 0.74
FNTB P49356 1/20 0.74
CRYAA P02489 1/20 0.71
ACHE P22303 1/20 0.62
MEN1 O00255 1/20 0.61
PLA2G1B P04054 1/20 0.61
DNMT1 P26358 1/20 0.61
BLM P54132 1/20 0.61
KMT2A Q03164 1/20 0.61
ATG4B Q9Y4P1 1/20 0.61
HMGCR P04035 1/20 0.61
PREP P48147 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lanosterol SCHEMBL16994483 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL145834 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14240642 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14536063 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL14360758 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL2154745 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL145835 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL1696473 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL19194030 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
Lanosterol SCHEMBL21348006 1.00 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11207333-B2 Compositions comprising triterpenoids and uses thereof for treating optic neuropathy REGENERA PHARMA LTD. (IL) 2021-12-28 US claimed
US-11173164-B2 Compositions comprising triterpenoids REGENERA PHARMA LTD. (IL) 2021-11-16 US claimed
EP-3352742-B1 COMPOSITIONS COMPRISING TRITERPENOIDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE REGENERA PHARMA LTD (IL) 2021-11-03 EP claimed
US-11083736-B2 Compositions comprising triterpenoids REGENERA PHARMA LTD. (IL) 2021-08-10 US claimed
US-20200155569-A1 COMPOSITIONS COMPRISING TRITERPENOIDS REGENERA PHARMA LTD. (IL) 2020-05-21 US claimed
US-10588911-B2 Compositions comprising triterpenoids REGENERA PHARMA LTD. (IL) 2020-03-17 US claimed
US-20190314389-A1 COMPOSITIONS COMPRISING TRITERPENOIDS REGENERA PHARMA LTD. (IL) 2019-10-17 US claimed
WO-2019170239-A1 TERPENE ENRICHED FRACTIONS FREE FROM POLYTERPENES EXTRACTED FROM CHIOS MASTIC GUM AND COSMETIC, NUTRACEUTICAL, MEDICAL DEVICES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PHYTOITALIA SRL (IT) 2019-09-12 WO claimed
US-20190224217-A1 COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY REGENERA PHARMA LTD. (IL) 2019-07-25 US claimed
EP-3509699-A1 COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY Regenera Pharma Ltd. (IL) 2019-07-17 EP claimed
US-20110136773-A1 Pharmaceutical Uses of Lanosta-8,24-dien-3-ols AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2011-06-09 US claimed
EP-2323666-A1 PHARMACEUTICAL USES OF LANOSTA-8,24-DIEN-3-OLS Amazonia Fitomedicamentos Ltda (BR) 2011-05-25 EP claimed
WO-2010015874-A1 PHARMACEUTICAL USES OF LANOSTA-8,24-DIEN-3-OLS AMAZONIA FITOMEDICAMENTOS LTDA (BR) 2010-02-11 WO claimed
WO-2006007676-A1 COMBINATION OF ACTIVE FRACTIONS FROM THE PLANTS EUPHORBIA TIRUCALLI L AND FICOS CARICA L. AND METHOD OF TREATING CANCER AND AIDS AMAZÔNIA FITOMEDICAMENTOS LTDA. (BR) 2006-01-26 WO claimed
US-20050238740-A1 Use of mastic and its components for the control of microbial infections THALLIUM HOLDING COMPANY, LLC 2005-10-27 US claimed
EP-1501527-A1 USE OF MASTIC AND ITS COMPONENTS FOR THE CONTROL OF MICROBIAL INFECTIONS LAVIPHARM S.A. (GR) 2005-02-02 EP claimed
WO-2003092712-A1 USE OF MASTIC AND ITS COMPONENTS FOR THE CONTROL OF MICROBIAL INFECTIONS LAVIPHARM S.A. (GR) 2003-11-13 WO claimed
US-4748161-A Triterpenyl esters of organic acids and hypolipidemic agents composed of them AMANO PHARMACEUTICAL CO., LTD. (JP) 1988-05-31 US claimed
CN-85109752-A Preparation triterpenoid organic acid ester and the method that contains the hypolipidemic agents of this compounds 1986-12-17 CN claimed
EP-0166542-A2 Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them AMANO PHARMACEUTICAL CO., LTD. (JP) 1986-01-02 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11207333-B2 Compositions comprising triterpenoids and uses thereof for treating optic neuropathy AQP4, CYP27A1, PMP22 MAPT 490/4885USP2 4207/4885ALDH1A1 1999/4885
US-11173164-B2 Compositions comprising triterpenoids PARK7, SNCA, APP MAPT 9/4885USP2 4026/4885ALDH1A1 3503/4885
US-20200155569-A1 COMPOSITIONS COMPRISING TRITERPENOIDS PARK7, SNCA, APP MAPT 9/4885USP2 4026/4885ALDH1A1 3503/4885
US-20190224217-A1 COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY AQP4, CYP27A1, PMP22 MAPT 490/4885USP2 4207/4885ALDH1A1 1999/4885
US-20190314389-A1 COMPOSITIONS COMPRISING TRITERPENOIDS CYP27A1, CYP11B2, CYP11B1 MAPT 1829/4885USP2 4142/4885ALDH1A1 2491/4885
US-11083736-B2 Compositions comprising triterpenoids CYP27A1, CYP11B2, CYP11B1 MAPT 1829/4885USP2 4142/4885ALDH1A1 2491/4885
US-10588911-B2 Compositions comprising triterpenoids PARK7, SNCA, APP MAPT 9/4885USP2 4026/4885ALDH1A1 3503/4885
US-20050238740-A1 Use of mastic and its components for the control of microbial infections CD14, RPL5, NFATC1 MAPT 4056/4885USP2 3365/4885ALDH1A1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.